Fibromyalgia Treatment  Market, By Drug Class (Antidepressants (Milnacipran (Savella and Other Generics), Duloxetine (Cymbalta and Other Generics), and Others), Antiepileptics (Pregabalin (Lyrica and Other Generics), and Others), Muscle Relaxants, Analgesics, and Others (Including Pipeline Drugs)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : May 2019 |
  • Pages : 176 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Fibromyalgia Treatment Market- Insights

Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue, and localized tenderness affecting individuals mentally, physically, and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain, and tender points. An individual with fibromyalgia can also have symptoms such as headaches, poor concentration, and depression. Fibromyalgia symptoms might accumulate with time or it can be caused by some external factors. Fibromyalgia treatments include therapy, medications, regular aerobic exercise, stress reduction, and others. Furthermore, for treatment of fibromyalgia, antidepressants or pain medications are prescribed to treat depression, anxiety, pain, and fatigue.

Robust pipeline of novel drugs are under late clinical trial phase for treatment of fibromyalgia

Market players are focusing on active research and development, in order to introduce new products in the market and increase treatment options. Approval and launch of novel fibromyalgia treatment drugs is expected to significantly support fibromyalgia treatment market growth over the forecast period.

For instance, manufacturers such as Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., Astellas Pharma, Inc., and others have drugs in the pipeline indicated for the treatment of fibromyalgia.

Many such drugs are in phase 2 and phase 3 of clinical trials with commercialization potential. For instance, Astellas Pharma, Inc. has ASP0819 in phase 2 and IMC-1 that received fast track designation from the U.S. FDA in 2016.

The global fibromyalgia treatment market size was valued at US$ 2,778.6 Mn in 2018 and is expected to witness a CAGR of 3.3% during the forecast period (2018 – 2026).

Figure 1. Global Fibromyalgia Treatment Market Share (%), By Drug Class, 2018-2026

Fibromyalgia Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

North America is expected to hold dominant position in the global fibromyalgia treatment market over the forecast period

North America fibromyalgia treatment market is expected to held largest share over the forecast period in the global fibromyalgia treatment market, owing to potential customer base, new product launches, and presence of leading manufacturers in the region.

Generic manufacturers such as Teva Pharmaceutical Industries Ltd., Mylan N.V., and others have launched generic drugs in North America region, which has supported growth of the market.

Although the overall market size has decreased due to patent loss and subsequent generic launches at low prices, two products still have patent protection i.e. Savella up to 2021 and Lyrica up to June 2019.

Originators of branded drugs suffered major revenue loss due to patent expiry (Cymbalta in 2013). However, arrival of various generic versions have resulted in increasing adoption rate due to lower prices, thereby driving the fibromyalgia treatment market growth.

Several manufacturers such as Aptinyx, Inc., Prismic Pharmaceuticals, Inc., and Innovative Med Concepts, Inc. have drugs in the pipeline for the treatment of fibromyalgia.

Figure 2. Global Fibromyalgia Treatment Market Share (%) Analysis, By Region, 2026

Fibromyalgia Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Restraints

There are currently only three U.S. Food & Drug Administration (FDA) approved medications available in the market, which include Cymbalta, Lyrica, and Savella. Other medications such as certain antidepressants (amitriptyline, fluoxetine, and others), antiepileptic drugs (gabapentin), and other treatments are used as an off-label medication for the treatment of fibromyalgia. Opioids are highly used in management of various pain conditions as well as fibromyalgia. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2012, around 260 million prescriptions were issued for opioid pain medication in the U.S. by healthcare providers, an increase of 300% as compared to the number of prescriptions written for the same in 1999. Moreover, prescriptions per capita increased by 7.3% from 2007 to 2012.

This factor is expected to affect growth of the global fibromyalgia treatment market up to certain extent along with the fact that there is no curative treatment available for fibromyalgia.

Market Opportunity

Currently, there are limited number of approved treatment options for fibromyalgia. Several manufacturers have potential candidates in the pipeline (some in late stages as well). Hence, new players in the market also have opportunity to develop new drug candidate for treatment of fibromyalgia.

Another opportunity is present in terms of generic drug manufacturing, as two of the drugs are expected to lose patent protection over the forecast period (Lyrica in 2019 and Savella in 2021, 2023, and 2029). Patent loss may be a restraint for the market, however, there is certainly an opportunity for generic manufacturers.

Key players operating in the fibromyalgia treatment market include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.

Fibromyalgia, also called fibromyalgia syndrome, is a chronic neurologic disorder, which causes severe pain all over the body. The cause of fibromyalgia is unknown, however, it can be caused due to various factors, including genetics cause, physical or emotional trauma or due to infections. The symptoms related to fibromyalgia includes widespread pain, severe fatigue, sleep problems, cognitive difficulties, and others. Various medications such as antidepressant drugs, antiepileptic drugs, muscle relaxants, and analgesics are used for the management and treatment of fibromyalgia.

Market Dynamics

Key players in the market are focusing on frequent research and development activities for development of novel medications for fibromyalgia treatment. Launch of novel drugs in the market for fibromyalgia is expected to boost the fibromyalgia treatment market growth over the forecast period. For instance, drug candidate IMC-1 is being developed by Innovative Med Concepts, which received fast track designation from the U.S. FDA in 2016

In December 2018, Aptinyx Inc. announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study received daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.

In 2017, Innovative Med Concepts announced that the Journal of Pain Research published the key topline results from the Phase 2 PRID-201 trial of IMC-1 for the treatment of fibromyalgia. This 16 week, randomized double-blinded, placebo-controlled study was conducted at 12 research centers in the U.S. and enrolled 143 patients with fibromyalgia, as defined by the ACR 2010 criteria. The PRID-201 study demonstrated that patients randomized to IMC-1 (celecoxib+famciclovir) experienced a significant decrease in fibromyalgia-related pain vs patients randomized to placebo.

Moreover, over the past few years, leading generic manufacturers such as Sun Pharmaceutical Industries Ltd., Mylan N.V., and Teva Pharmaceuticals Industries Ltd. have launched generic drugs for fibromyalgia treatment in the market.

Launch of generic versions of branded fibromyalgia drugs is expected to affect the revenue of branded drugs. However, it is expected to increase adoption and affordability of drugs and support fibromyalgia treatment market growth in the near future.

For instance, in December 2013, Sun Pharmaceutical Industries Ltd. announced that the U.S. FDA granted approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta, Duloxetine Delayed-Release Capsules USP, 20 mg, 30 mg, and 60 mg.

Key features of the study:

  • This report provides in-depth analysis of fibromyalgia treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global fibromyalgia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global fibromyalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the fibromyalgia treatment market

Detailed Segmentation:

  • Global Fibromyalgia Treatment Market, By Drug Class :
    • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
    • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
    • Muscle Relaxants
    • Analgesics
    • Others (Including Pipeline Drugs)
  • Global Fibromyalgia Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Fibromyalgia Treatment Market, By Region:
    • North America
      • By Drug Class :
        • Antidepressants
          • Milnacipran (Savella and Other Generics)
          • Duloxetine (Cymbalta and Other Generics)
          • Others
        • Antiepileptics
          • Pregabalin (Lyrica and Other Generics)
          • Others
        • Muscle Relaxants
        • Analgesics
        • Others (Including Pipeline Drugs)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Class :
        • Antidepressants
          • Milnacipran (Savella and Other Generics)
          • Duloxetine (Cymbalta and Other Generics)
          • Others
        • Antiepileptics
          • Pregabalin (Lyrica and Other Generics)
          • Others
        • Muscle Relaxants
        • Analgesics
        • Others (Including Pipeline Drugs)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class :
        • Antidepressants
          • Milnacipran (Savella and Other Generics)
          • Duloxetine (Cymbalta and Other Generics)
          • Others
        • Antiepileptics
          • Pregabalin (Lyrica and Other Generics)
          • Others
        • Muscle Relaxants
        • Analgesics
        • Others (Including Pipeline Drugs)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Class :
        • Antidepressants
          • Milnacipran (Savella and Other Generics)
          • Duloxetine (Cymbalta and Other Generics)
          • Others
        • Antiepileptics
          • Pregabalin (Lyrica and Other Generics)
          • Others
        • Muscle Relaxants
        • Analgesics
        • Others (Including Pipeline Drugs)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Drug Class :
        • Antidepressants
          • Milnacipran (Savella and Other Generics)
          • Duloxetine (Cymbalta and Other Generics)
          • Others
        • Antiepileptics
          • Pregabalin (Lyrica and Other Generics)
          • Others
        • Muscle Relaxants
        • Analgesics
        • Others (Including Pipeline Drugs)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class :
        • Antidepressants
          • Milnacipran (Savella and Other Generics)
          • Duloxetine (Cymbalta and Other Generics)
          • Others
        • Antiepileptics
          • Pregabalin (Lyrica and Other Generics)
          • Others
        • Muscle Relaxants
        • Analgesics
        • Others (Including Pipeline Drugs)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Eli Lilly and Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Pfizer, Inc.
    • Novartis AG
    • Allergan plc.
    • Sun Pharmaceutical Industries Ltd.
    • Aptinyx, Inc.
    • Prismic Pharmaceuticals, Inc.
    • Innovative Med Concepts, Inc.
    • Intec Pharma Ltd.
    • Astellas Pharma Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Patent Litigations
    • Reimbursement
    • Patent Landscape (ANDA/NDA Intelligence)
    • PEST Analysis
    • Porter’s Analysis
  4. Global Fibromyalgia Treatment Market, By Drug Class, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Antidepressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
      • Segment Trends
        • Milnacipran (Savella and Other Generics)
        • Duloxetine (Cymbalta and Other Generics)
        • Others
    • Antiepileptics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
      • Segment Trends
        • Pregabalin (Lyrica and Other Generics)
        • Others
    • Muscle Relaxants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Others (Including Pipeline Drugs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  5. Global Fibromyalgia Treatment Market, By Distribution Channel, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global Fibromyalgia Treatment Market, By Region, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017–2026
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2026 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Allergan plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Aptinyx, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Prismic Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Innovative Med Concepts, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Intec Pharma Ltd
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Astellas Pharma Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 35 figures on “Fibromyalgia Treatment Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.